{"name":"David Rizzieri, MD","slug":"david-rizzieri-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Campath Purged Non-myeloablative ASCT","genericName":"Campath Purged Non-myeloablative ASCT","slug":"campath-purged-non-myeloablative-asct","indication":"Chronic lymphocytic leukemia (CLL)","status":"phase_2"}]}],"pipeline":[{"name":"Campath Purged Non-myeloablative ASCT","genericName":"Campath Purged Non-myeloablative ASCT","slug":"campath-purged-non-myeloablative-asct","phase":"phase_2","mechanism":"Campath (Alemtuzumab) is a monoclonal antibody that targets CD52, a protein found on the surface of mature lymphocytes.","indications":["Chronic lymphocytic leukemia (CLL)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE1sLXctbjhmNnBZMzZhNHhuTVpvSzZ1SExaZ1J4YWFLN3NSYndDRHRSR2dqUnVFdDRJTXVoamJ4Yy1Ud21vdTVpQmJwRmhDNmI3NHc2d0hoVl9pT2xVVHhlcjlBMGJEZlVFRnZabDRtU3M4YXNLY1VDaE9pZw?oc=5","date":"2017-12-06","type":"pipeline","source":"Wiley","summary":"Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia - Wiley","headline":"Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE5hbWhmRXMzb1k0UXprYmNrTVdCem5YdkN5UlViNGYtczlnZWZEbUJHRThlTUloN3F1RGhQLWV2bVpWLWppR2hnMm9JUkdnNS1fVzJsMktIQUg4b3RjaDFhZXRkS09rNmg2QVRwSUprZmxzeExZajcwRVZLNA?oc=5","date":"2013-03-11","type":"pipeline","source":"ProPublica","summary":"Dollars for Docs Mints a Millionaire - ProPublica","headline":"Dollars for Docs Mints a Millionaire","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQaFphM1ZicFJIOWZZM2l1QnVQRUhsWjgxM2JneVkzQlZ3TmY2TGV4SmdFVklmWkhmbE04SGUzckVQN1NDVDVkTHZZejFtaDYyRU01WndrRm5iRXI4WEVoSVhlMnVZR0xSajVxQng1MExqN24tZDM0OVJlX2trbURSLVN5V3N4SHN5?oc=5","date":"2010-11-01","type":"pipeline","source":"ProPublica","summary":"Dollars for Docs: Who’s On Pharma’s Top-Paid List? - ProPublica","headline":"Dollars for Docs: Who’s On Pharma’s Top-Paid List?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE1FVTZkek9UTS1XTUxvX29wcktyX1dmUElnRTYzWW1mNGVZUC1xRnAyZDdjSnIwSzJKRndXZjhOdHdteWFWNFhiWlVCVkh2ZWNGUGxOVllLTjNjTzR2a0JvN1RBc2dYSWJvel8xb01LTzRwbFFxWlpDSi1wWQ?oc=5","date":"2004-04-16","type":"pipeline","source":"Wiley","summary":"Low‐dose weekly paclitaxel for recurrent or refractory aggressive non‐Hodgkin lymphoma - Wiley","headline":"Low‐dose weekly paclitaxel for recurrent or refractory aggressive non‐Hodgkin lymphoma","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}